Restoring balance.
Renewing life.

Akero is pioneering novel therapies to transform the lives of people living with serious metabolic diseases.
Learn More
Learn More

Advancing Efruxifermin (EFX) for MASH

Our flagship EFX program is designed to be a differentiated, potentially best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)

Learn more

Ongoing Clinical Studies

We have multiple ongoing clinical trials to evaluate our investigational drug, EFX, as a treatment for MASH.

Learn more

Recent Press Releases from Akero

11/08/2024

Akero Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

10/21/2024

Akero Therapeutics to Present Data Reinforcing the Efficacy of Efruxifermin at the 75th Annual AASLD The Liver Meeting® 2024

09/30/2024

Akero Therapeutics to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference

View All

We’re looking for talented individuals driven to make a difference for patients.

See Open Positions

We’re looking for talented individuals driven to make a difference for patients.

See Open Positions